LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Involving Patients and Clinicians in the Design of Wireframes for Cancer Medicines Electronic Patient Reported Outcome Measures in Clinical Care: Mixed Methods Study.

    Dunlop, Emma / Ferguson, Aimee / Mueller, Tanja / Baillie, Kelly / Laskey, Jennifer / Clarke, Julie / Kurdi, Amanj / Wales, Ann / Connolly, Thomas / Bennie, Marion

    JMIR formative research

    2023  Volume 7, Page(s) e48296

    Abstract: Background: Cancer treatment is a key component of health care systems, and the increasing number of cancer medicines is expanding the treatment landscape. However, evidence of the impact on patients has been focused more on chemotherapy toxicity and ... ...

    Abstract Background: Cancer treatment is a key component of health care systems, and the increasing number of cancer medicines is expanding the treatment landscape. However, evidence of the impact on patients has been focused more on chemotherapy toxicity and symptom control and less on the effect of cancer medicines more broadly on patients' lives. Evolving electronic patient-reported outcome measures (ePROMs) presents the opportunity to secure early engagement of patients and clinicians in shaping the collection of quality-of-life metrics and presenting these data to better support the patient-clinician decision-making process.
    Objective: The aim of this study was to obtain initial feedback from patients and clinicians on the wireframes of a digital solution (patient app and clinician dashboard) for the collection and use of cancer medicines ePROMs.
    Methods: We adopted a 2-stage, mixed methods approach. Stage 1 (March to June 2019) consisted of interviews and focus groups with cancer clinicians and patients with cancer to explore the face validity of the wireframes, informed by the technology acceptance model constructs (perceived ease of use, perceived usefulness, and behavioral intention to use). In stage 2 (October 2019 to February 2020), the revised wireframes were assessed through web-based, adapted technology acceptance model questionnaires. Qualitative data (stage 1) underwent a framework analysis, and descriptive statistics were performed on quantitative data (stage 2). Clinicians and patients with cancer were recruited from NHS Greater Glasgow & Clyde, the largest health board in Scotland.
    Results: A total of 14 clinicians and 19 patients participated in a combination of stage 1 interviews and focus groups. Clinicians and patients indicated that the wireframes of a patient app and clinician dashboard for the collection of cancer medicines ePROMs would be easy to use and could focus discussions, and they would be receptive to using such tools in the future. In stage 1, clinicians raised the potential impact on workload, and both groups identified the need for adequate IT skills to use each technology. Changes to the wireframes were made, and in stage 2, clinicians (n=8) and patients (n=16) indicated it was "quite likely" that the technologies would be easy to use and they would be "quite likely" to use them in the future. Notably, clinicians indicated that they would use the dashboard to enable treatment decisions "with around half" of their patients.
    Conclusions: This study emphasizes the importance of consulting both patients and clinicians in the design of digital solutions. The wireframes were perceived positively by patients and clinicians who were willing to use such technologies if available in the future as part of routine care. However, challenges were raised, and some differences were identified between participant groups, which warrant further research.
    Language English
    Publishing date 2023-12-21
    Publishing country Canada
    Document type Journal Article
    ISSN 2561-326X
    ISSN (online) 2561-326X
    DOI 10.2196/48296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018.

    Clarke, Julie / Bennie, Marion / Kurdi, Amanj / Pan, Jiafeng / Mueller, Tanja / Crearie, Christine / Baillie, Kelly / Laskey, Jennifer / Waterston, Ashita

    Future oncology (London, England)

    2023  Volume 19, Issue 6, Page(s) 451–461

    Abstract: Aim: ...

    Abstract Aim:
    MeSH term(s) Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Immunotherapy ; Ipilimumab ; Melanoma/drug therapy ; Neoplasms, Second Primary ; Retrospective Studies ; Scotland/epidemiology
    Chemical Substances Ipilimumab
    Language English
    Publishing date 2023-04-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2022-0959
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice.

    Mueller, Tanja / Laskey, Jennifer / Baillie, Kelly / Clarke, Julie / Crearie, Christine / Kavanagh, Kimberley / Graham, Janet / Graham, Kathryn / Waterson, Ashita / Jones, Robert / Kurdi, Amanj / Morrison, David / Bennie, Marion

    Health informatics journal

    2022  Volume 28, Issue 1, Page(s) 14604582221077055

    Abstract: The efficacy and safety of cancer medicines as reported from randomised clinical trials do not always translate into similar benefits in routine clinical practice; hence, post-marketing studies are a useful addition to the evidence base. With recent ... ...

    Abstract The efficacy and safety of cancer medicines as reported from randomised clinical trials do not always translate into similar benefits in routine clinical practice; hence, post-marketing studies are a useful addition to the evidence base. With recent advances in digital infrastructure and the advent of electronically available health records, linkage of routinely collected data has emerged as a promising evaluation method for these studies. This paper discusses the opportunities and challenges when applying an electronic record linkage methodology with respect to systemic anti-cancer therapy by showcasing exemplar studies conducted over a three-year period in Scotland, and highlights some of the potential pitfalls spanning the entire breadth and depth of the research process. Our experiences as an interdisciplinary team indicate that there is scope to conduct large cohort studies to generate results from routine clinical practice within a reasonable time frame; however, close collaboration between researchers, data controllers and clinicians is required in order to obtain valid and meaningful results.
    MeSH term(s) Delivery of Health Care ; Electronics ; Humans ; Neoplasms/drug therapy ; Scotland
    Language English
    Publishing date 2022-02-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2213115-2
    ISSN 1741-2811 ; 1460-4582
    ISSN (online) 1741-2811
    ISSN 1460-4582
    DOI 10.1177/14604582221077055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide.

    Rana, Dikshyanta / Geue, Claudia / Baillie, Kelly / Pan, Jiafeng / Mueller, Tanja / Laskey, Jennifer / Bennie, Marion / Clarke, Julie / Jones, Robert J / Brown, Ailsa / Wu, Olivia

    PharmacoEconomics - open

    2021  Volume 6, Issue 2, Page(s) 303–313

    Abstract: Objective: The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated ( ... ...

    Abstract Objective: The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received docetaxel-based chemotherapy (post-chemotherapy), before commencing these medicines.
    Methods: A retrospective cost analysis of mCRPC patients who commenced abiraterone or enzalutamide between 2012 and 2015 was conducted. Routinely collected datasets from the largest health board in Scotland and the UK, Greater Glasgow and Clyde, were linked. They contained information on patient demographics, diagnosis, outpatient consultations, hospital admissions, treatments (abiraterone and enzalutamide), and supportive medicines. Unit costs were obtained from the Scottish Health Service Costs, Personal Social Services Research Unit, and British National Formulary. Generalised linear model-based regression was used to estimate total mean direct costs, and two-part models were used to estimate separate cost components. All models were adjusted for propensity score and key variables. Sensitivity analysis was conducted to explore the impact of hypothetical patient access scheme discounts.
    Results: Estimated total mean direct medical costs of treating mCRPC patients were similar, albeit with wide and overlapping confidence intervals. Across both treatments, patients who received abiraterone or enzalutamide in a pre-chemotherapy setting incurred the highest total mean direct medical costs. However, post-chemotherapy patients were associated with higher outpatient clinic visits, inpatient hospital admissions, and supportive medicines. Regarding relative contribution to the total mean direct medical cost, the treatment costs were the main contributor, followed by inpatient admissions, outpatient clinic visits, and supportive medicines.
    Conclusion: The total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data.
    Language English
    Publishing date 2021-11-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2874287-4
    ISSN 2509-4254 ; 2509-4262
    ISSN (online) 2509-4254
    ISSN 2509-4262
    DOI 10.1007/s41669-021-00307-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer.

    Dunlop, Emma / Ferguson, Aimee / Mueller, Tanja / Baillie, Kelly / Clarke, Julie / Laskey, Jennifer / Kurdi, Amanj / Wu, Olivia / Jones, Rob / Glen, Hilary / Bennie, Marion

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

    2021  Volume 30, Issue 4, Page(s) 3141–3150

    Abstract: Objective: To identify what matters to clinicians and patients when discussing cancer medicines' impact on health-related quality of life (HRQoL).: Methods: A framework of HRQoL domain/domain elements was developed, informed by analysis of published ... ...

    Abstract Objective: To identify what matters to clinicians and patients when discussing cancer medicines' impact on health-related quality of life (HRQoL).
    Methods: A framework of HRQoL domain/domain elements was developed, informed by analysis of published patient reported outcome measures (PROMs), applicable to prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique and questionnaire), prostate cancer clinicians and patients attending prostate cancer clinics and support groups were asked which domains/domain elements would be important to them when discussing the impact prostate cancer medicines have on their HRQoL.
    Results: Twenty-one clinicians and 71 patients participated from the West of Scotland. Clinicians and patients identified 53/62 domain elements across seven domains as important, of which 32 (60%) were common to both groups. Clinicians placed more importance than patients on Mood & Emotion; in contrast, patients placed importance on a broader range of Symptoms & Side Effects, being informed about their care, and having effective healthcare professional collaboration.
    Conclusion: This study provides insight into the similarities and differences between what clinicians and patients think is important when discussing the impact of cancer medicines on HRQoL. Future research should involve exploring the potential for consistency of medicines PROMs across different cancer types to support patient-clinician communication and drive improvements in care.
    MeSH term(s) Consensus ; Humans ; Male ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/psychology ; Quality of Life ; Surveys and Questionnaires
    Language English
    Publishing date 2021-12-08
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1134446-5
    ISSN 1433-7339 ; 0941-4355
    ISSN (online) 1433-7339
    ISSN 0941-4355
    DOI 10.1007/s00520-021-06724-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.

    Baillie, Kelly / Mueller, Tanja / Pan, Jiafeng / Laskey, Jennifer / Bennie, Marion / Crearie, Christine / Kavanagh, Kimberley / Alvarez-Madrazo, Samantha / Morrison, David / Clarke, Julie / Keel, Aileen / Cameron, David / Wu, Olivia / Kurdi, Amanj / Jones, Robert J

    Pharmacoepidemiology and drug safety

    2020  Volume 29, Issue 6, Page(s) 653–663

    Abstract: Purpose: New treatments are introduced into standard care based on clinical trial results. However, it is not clear if these benefits are reflected in the broader population. This study analysed the clinical outcomes of patients with metastatic ... ...

    Abstract Purpose: New treatments are introduced into standard care based on clinical trial results. However, it is not clear if these benefits are reflected in the broader population. This study analysed the clinical outcomes of patients with metastatic castration-resistant prostate cancer, treated with abiraterone and enzalutamide, within the Scottish National Health Service.
    Methods: Retrospective cohort study using record linkage of routinely collected healthcare data (study period: February 2012 to February 2017). Overall survival (OS) was analysed using Kaplan-Meier methods and Cox Proportional Hazard models; a subgroup analysis comprised potentially trial-eligible patients.
    Results: Overall, 271 patients were included and 73.8% died during the study period. Median OS was poorer than in the pivotal trials, regardless of medication and indication: 10.8 months (95% confidence interval [CI] 8.6-15.1) and 20.9 months (95% CI 14.9-29.0) for abiraterone, and 12.6 months (95% CI 10.5-18.2) and 16.0 months (95% CI 9.8-not reached) for enzalutamide, post and pre chemotherapy, respectively. Only 46% of patients were potentially "trial eligible" and in this subgroup OS improved. Factors influencing survival included baseline performance status, and baseline prostate-specific antigen, alkaline phosphatase, and albumin levels.
    Conclusions: Poorer prognostic features of non-trial eligible patients impact real-world outcomes of cancer medicines. Electronic record linkage of routinely collected healthcare data offers an opportunity to report outcomes on cancer medicines at scale and describe population demographics. The availability of such observational data to supplement clinical trial results enables patients and clinicians to make more informed treatment decisions, and policymakers to contextualise trial findings.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Androgen Antagonists/therapeutic use ; Androstenes/adverse effects ; Androstenes/therapeutic use ; Clinical Decision-Making ; Clinical Trials as Topic ; Electronic Health Records ; Eligibility Determination ; Humans ; Male ; Medical Record Linkage ; Middle Aged ; Neoplasm Metastasis ; Patient Selection ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Scotland ; State Medicine ; Time Factors ; Treatment Outcome
    Chemical Substances Androgen Antagonists ; Androstenes ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU) ; abiraterone (G819A456D0)
    Language English
    Publishing date 2020-04-21
    Publishing country England
    Document type Comparative Study ; Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099748-9
    ISSN 1099-1557 ; 1053-8569
    ISSN (online) 1099-1557
    ISSN 1053-8569
    DOI 10.1002/pds.4998
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.

    Rulach, Robert J / McKay, Stephen / Neilson, Sam / White, Lillian / Wallace, Jan / Carruthers, Ross / Lamb, Carolynn / Cascales, Almudena / Marashi, Husam / Glen, Hilary / Venugopal, Balaji / Sadoyze, Azmat / Sidek, Norma / Russell, J Martin / Alhasso, Abdulla / Dodds, David / Laskey, Jennifer / Jones, Robert J / MacLeod, Nicholas

    BJU international

    2017  

    Abstract: Objectives: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical trial.: Patients and methods: Patients in the West of Scotland ... ...

    Abstract Objectives: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical trial.
    Patients and methods: Patients in the West of Scotland Cancer Network with newly diagnosed mPC were identified from the regional multidisciplinary team meetings and their treatment details were collected from electronic patient records. The rate of febrile neutropenia, hospitalisations, time to progression, and overall survival were compared between those patients who received docetaxel and androgen-deprivation therapy (ADT), or ADT alone using survival analysis.
    Results: Of the 270 eligible patients, 103 received docetaxel (38.1%). 35 patients (34%) were hospitalised and there were 17 episodes of febrile neutropenia (16.5%). Two patients (1.9%) died within 30 days of chemotherapy. Patients who received ADT alone had an increased risk of progression (hazard ratio [HR] 2.03, 95% confidence interval [CI] 1.27-3.25; log-rank test, P = 0.002) and had an increased risk of death (HR 5.88, 95% CI: 2.52-13.72; log-rank test, P = 0.001) compared to the docetaxel group. The risk of febrile neutropenia was nine-times greater if chemotherapy was started within 3 weeks of ADT initiation (95% CI: 1.22-77.72; P = 0.032).
    Conclusion: Docetaxel chemotherapy in hormone-naïve mPC has significant toxicities, but has a similar effect on time to progression and overall survival as seen in randomised trials. Chemotherapy should be started at ≥3 weeks after ADT.
    Language English
    Publishing date 2017-09-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 1462191-5
    ISSN 1464-410X ; 1464-4096 ; 1358-8672
    ISSN (online) 1464-410X
    ISSN 1464-4096 ; 1358-8672
    DOI 10.1111/bju.14025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top